康惠制药
(603139)
| 流通市值：19.38亿 | | | 总市值：19.38亿 |
| 流通股本：9988.00万 | | | 总股本：9988.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 121,353,198.96 | 561,634,852.83 | 404,545,531.96 | 265,668,337.76 |
| 营业收入 | 121,353,198.96 | 561,634,852.83 | 404,545,531.96 | 265,668,337.76 |
| 二、营业总成本 | 150,382,034.67 | 637,858,647.3 | 455,454,003.35 | 288,768,212.05 |
| 营业成本 | 91,664,155.74 | 388,590,764.27 | 274,500,711.5 | 178,764,263.19 |
| 税金及附加 | 3,668,864.53 | 12,264,897.73 | 9,261,537.52 | 6,758,566.88 |
| 销售费用 | 31,415,973.16 | 140,324,467.35 | 105,421,513.96 | 60,301,862.14 |
| 管理费用 | 13,675,822.6 | 55,977,746.65 | 39,052,974.64 | 24,919,425.53 |
| 研发费用 | 1,814,517.83 | 8,316,553.72 | 4,697,380.27 | 3,386,639.75 |
| 财务费用 | 8,142,700.81 | 32,384,217.58 | 22,519,885.46 | 14,637,454.56 |
| 其中:利息费用 | 10,860,209.55 | 34,788,130.65 | 25,377,613.47 | 16,065,406.22 |
| 其中:利息收入 | 534,174.22 | 2,715,738.04 | 2,466,449.88 | 1,519,262 |
| 加:公允价值变动收益 | - | -86,132 | 2,061,918 | 1,261,918 |
| 加:投资收益 | - | -31,062,163.1 | 2,304,092.47 | 11,507,042.46 |
| 资产处置收益 | 5,032 | 161,821.71 | -34,282.31 | -34,282.31 |
| 资产减值损失(新) | - | -16,112,103.62 | -766,663.32 | 927.91 |
| 信用减值损失(新) | -57,286.31 | -6,832,233.62 | -3,896,391.46 | -3,076,546.94 |
| 其他收益 | 1,791,194.34 | 7,163,733.58 | 5,260,048.68 | 4,091,129.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -27,289,895.68 | -122,990,871.52 | -45,979,749.33 | -9,349,685.52 |
| 加:营业外收入 | 33,360.92 | 3,602,075.48 | 441,174.67 | 145,569.54 |
| 减:营业外支出 | 3,085.83 | 2,151,579.82 | 715,605.86 | 677,679.08 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -27,259,620.59 | -121,540,375.86 | -46,254,180.52 | -9,881,795.06 |
| 减:所得税费用 | 196,564.3 | -9,543,027.21 | 1,528,033.33 | 7,226,599.16 |
| 六、净利润 | -27,456,184.89 | -111,997,348.65 | -47,782,213.85 | -17,108,394.22 |
| 持续经营净利润 | -27,456,184.89 | -111,997,348.65 | -47,782,213.85 | -17,108,394.22 |
| 归属于母公司股东的净利润 | -17,239,346.14 | -89,625,540.62 | -38,288,437.47 | -8,701,972.53 |
| 少数股东损益 | -10,216,838.75 | -22,371,808.03 | -9,493,776.38 | -8,406,421.69 |
| (一)基本每股收益 | -0.17 | -0.9 | -0.38 | -0.09 |
| (二)稀释每股收益 | -0.17 | -0.9 | -0.38 | -0.09 |
| 八、其他综合收益 | - | -2,407,316.57 | - | - |
| 归属于母公司股东的其他综合收益 | - | -2,407,316.57 | - | - |
| 九、综合收益总额 | -27,456,184.89 | -114,404,665.22 | -47,782,213.85 | -17,108,394.22 |
| 归属于母公司股东的综合收益总额 | -17,239,346.14 | -92,032,857.19 | -38,288,437.47 | -8,701,972.53 |
| 归属于少数股东的综合收益总额 | -10,216,838.75 | -22,371,808.03 | -9,493,776.38 | -8,406,421.69 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |